APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/06/2026
Voltar para busca
Dado oficial do USPTO
PKANALIX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
02/06/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
9, 42
Data de depósito
26/04/2019
Data de registro
17/03/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/03/2020
Última transação
02/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
98
Localização do titular
FR
Examinador
MCDOWELL, MATTHEW J
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "PKanalix" in a stylized font.
Titulares e representantes
Titulares
S. F. (pessoa física)
LIXOFT
Representantes
Cathleen E. Stadecker Downs Rachlin Martin PLLC
Classificação técnica
Classes Nice
Classe 9Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
Electric and electronic apparatus and instrumentscomputer hardware and recorded software sold as a unit for the measuringstorageencodingmemorizingindicatinganalysisprocessingproduction and transmission of data and signals; digital simulation devices and instrumentsmedical simulators for use in the process of clinical trialsof pre-clinical trialsof drug development and of individualized optimization of therapeutic treatments; devices and instruments for graphics and statistical analysiscomputers; apparatus for the recordingtransmission or reproduction of data; signal receiving terminalsreceivers of electronic signals; blank magnetic data carriersblank recordable optical discs for sound recording; data processing equipment and computers; integrated circuit cardsblank smart cards; computers and computer peripherals; computer parts and components for visual and graphic data and information processingdevelopment and displaycomputer peripheral devices; recorded downloadable computer software for population analysis in pre-clinical and clinical trialsfor customized optimization of therapeutic treatmentsfor mathematical modelling and simulationfor reporting the concentration of drugs in patients during a treatment and for statistical and data analysis; recorded downloadable computer software for pharmacokinetic data analysis; recorded downloadable computer software for use for controlling and managing patient medical informationdrug efficiency and drug concentration in patients during a treatment for medical use; recorded downloadable computer software used to process and interpret diagnostic test results; recorded downloadable computer software for collectingstoring and processing dataimagesphotographsaudiovisual and audio-visual data; recorded downloadable database management software; recorded computer software for database server centers; computer apparatuscomputers and computer peripherals for providing access to data banks; downloadable recorded computer software for accessingbrowsing and searching online databases
Classe 42
Evaluationsassessments and research in the scientifictechnological and medical fields provided by engineersengineering services; Engineering services involving evaluationsestimatesresearch and reporting in scientifictechnological and medical fields; medical and scientific research in the field of pharmacokinetic data analysis; laboratory services for scientific and medical research; conducting clinical trials for others; research and development of new products for third parties; technical project studiesdrug and medical devices discovery servicesdesign and development of drugsmodelingsimulationstatistics and data analysis; design and development of computers and software; research in the field of software; developmentdesigninstallationmaintenanceupdating and rental of software; computer programming; providing information with respect to medical research; assistance in the nature of advice and consulting in connection with the development of systemsdatabases and computer applications; conversion of computer programs and dataother than physical conversion; informationadvicesupport services in the nature of troubleshooting of computer software problems relating to any of the aforementioned services
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
ES75
TEAS SECTION 71 & 15 RECEIVED
11/02/2026
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
25/04/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
17/03/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
20/12/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
29/11/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
14/08/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
28/07/2020
FIMP
FINAL DISPOSITION PROCESSED
28/07/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/06/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
17/03/2020
GPNX
NOTIFICATION PROCESSED BY IB
04/01/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
31/12/2019
PUBO
PUBLISHED FOR OPPOSITION
31/12/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/12/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/12/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/12/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/11/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/11/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/10/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/10/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/10/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/10/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/10/2019
RFNT
REFUSAL PROCESSED BY IB
20/09/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/09/2019
RFRR
REFUSAL PROCESSED BY MPU
04/09/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/08/2019
CNRT
NON-FINAL ACTION WRITTEN
15/08/2019
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
12/08/2019
MAFR
APPLICATION FILING RECEIPT MAILED
24/07/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
21/07/2019
CNRT
NON-FINAL ACTION WRITTEN
20/07/2019
DOCK
ASSIGNED TO EXAMINER
20/07/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/07/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
18/07/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PKANALIX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.